Valuation: Pharmigene, Inc.

Market Cap 35Cr 1.11Cr 99.12L 92.35L 84.04L 1.58Cr 107.01Cr 1.59Cr 11Cr 4.34Cr 55Cr 4.17Cr 4.08Cr 175.55Cr P/E 2024
-8.68x
P/E 2025 -6.84x
Enterprise Value 92Cr 2.91Cr 2.59Cr 2.41Cr 2.2Cr 4.14Cr 279.79Cr 4.17Cr 29Cr 11Cr 142.8Cr 11Cr 11Cr 459.01Cr EV / Sales 2024
10.1x
EV / Sales 2025 5.35x
Free-Float
49.29%
Yield 2024 *
-
Yield 2025 -
1 day-3.62%
1 week+1.84%
Current month+0.42%
1 month-1.78%
3 months+5.12%
6 months-28.91%
Current year-27.47%
1 week 6.8
Extreme 6.8
7.51
1 month 6.7
Extreme 6.7
7.51
Current year 5.9
Extreme 5.9
11.85
1 year 5.9
Extreme 5.9
12.3
3 years 5.9
Extreme 5.9
23.5
5 years 5.9
Extreme 5.9
25.7
10 years 5.9
Extreme 5.9
36
Manager TitleAgeSince
Chief Executive Officer 67 04/11/2019
Chief Operating Officer 49 04/11/2019
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 67 -
Director/Board Member 35 04/11/2019
Director/Board Member 65 07/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
-3.62%+1.84%-40.41%-69.18% 1.18Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-0.37%-3.81%+19.51%+78.12% 5.74TCr
+1.63%-1.61%+3.16%+36.89% 4.76TCr
+0.71%+3.23%+347.10%+724.47% 4.43TCr
+2.28%-2.64%+28.68%+33.36% 4.25TCr
+1.35%-1.37%+5.06%+112.09% 4.07TCr
-0.54%+2.93%+9.31%+54.06% 3.1TCr
+1.56%+4.53%+31.34%+26.92% 2.85TCr
+1.48%-1.00%-6.72%-10.71% 2.43TCr
Average +0.85%-0.40%+44.64%+108.02% 3.91TCr
Weighted average by Cap. +1.54%-0.84%+58.25%+136.92%

Financials

2024 2025
Net sales 12Cr 36.71L 32.75L 30.51L 27.76L 52.28L 35Cr 52.67L 3.69Cr 1.43Cr 18Cr 1.38Cr 1.35Cr 58Cr 20Cr 62.96L 56.17L 52.33L 47.62L 89.68L 61Cr 90.35L 6.32Cr 2.46Cr 31Cr 2.36Cr 2.31Cr 99Cr
Net income -8.29Cr -26.1L -23.28L -21.69L -19.74L -37.18L -25Cr -37.45L -2.62Cr -1.02Cr -13Cr -97.98L -95.87L -41Cr -7.3Cr -22.99L -20.51L -19.11L -17.39L -32.75L -22Cr -32.99L -2.31Cr -89.83L -11Cr -86.31L -84.45L -36Cr
Net Debt 46Cr 1.44Cr 1.29Cr 1.2Cr 1.09Cr 2.05Cr 138.89Cr 2.07Cr 14Cr 5.63Cr 71Cr 5.41Cr 5.3Cr 227.85Cr 57Cr 1.79Cr 1.6Cr 1.49Cr 1.36Cr 2.56Cr 172.79Cr 2.57Cr 18Cr 7.01Cr 88Cr 6.74Cr 6.59Cr 283.46Cr
Logo Pharmigene, Inc.
Pharmigene Inc is mainly engaged in drug gene diagnosis, functional medical testing services and agency sales of laboratory equipment and consumables. The Company mainly engages in field of genomics science, developing professional drug genetic diagnostic kits, testing technologies, and overall solutions for the research and development of drug genomics in precision medicine. The Company's molecular diagnostic products mainly include AutoEx16 automatic nucleic acid extractor, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kit, SGE 1502 test suite, SGE 3101 test suite, SGE 5701 test suite, Sega 5801 test kit, SGE B27 test kit, SGE whole blood calculation and extraction kit and others. Testing services include drug genetic testing projects, functional medical testing projects and personalized genetic testing. The Company mainly distributes its products in Taiwan market and other markets.
Employees
-
Date Price Change Volume
05/26/05 NT$7.180 -3.62% 16,032
02/26/02 NT$7.450 +4.20% 80,560
01/26/01 NT$7.150 0.00% 11,010
30/26/30 NT$7.150 +0.85% 13,021
  1. Stock Market
  2. Stocks
  3. 7595 Stock